AFT Pharmaceuticals (NZSE:AFT) ROCE %: 29.30% (As of Mar. 2026)


NZSE:AFT AFT Pharmaceuticals Ltd NZSE:AFT
95 GF Score
Price NZ$3.91
GF Value NZ$4.18
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is AFT Pharmaceuticals ROCE %?

AFT Pharmaceuticals NZSE:AFT 95 ROCE % is 29.30% as of Mar. 2026. GuruFocus rates NZSE:AFT with a GF Score™ of 95/100 and a GF Value™ of NZ$4.18 (Fairly Valued). The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. AFT Pharmaceuticals's annualized ROCE % for the quarter that ended in Mar. 2026 was 29.30%.

AFT Pharmaceuticals  (NZSE:AFT) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

AFT Pharmaceuticals ROCE % Related Terms

AFT Pharmaceuticals ROCE % Historical Data

* Premium members only.

The historical data trend for AFT Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AFT Pharmaceuticals ROCE % Chart

AFT Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 25.17 18.35 22.33 15.12 17.38

AFT Pharmaceuticals Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 37.64 -2.52 33.08 9.97 29.30
NZSE:AFT
95GF Score
AFT Pharmaceuticals Ltd NZSE:AFT
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AFT Pharmaceuticals ROCE % Calculation

AFT Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=24.091/( ( (169.815 - 43.256) + (217.01 - 66.347) )/ 2 )
=24.091/( (126.559+150.663)/ 2 )
=24.091/138.611
=17.38 %

AFT Pharmaceuticals's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Sep. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Sep. 2025 )(Q: Mar. 2026 )
=36.848/( ( (171.622 - 70.764) + (217.01 - 66.347) )/ 2 )
=36.848/( ( 100.858 + 150.663 )/ 2 )
=36.848/125.7605
=29.30 %

(1) Note: The EBIT data used here is two times the semi-annual (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 29.30% mean?
AFT Pharmaceuticals (NZSE:AFT) has a ROCE % of 29.30% as of Mar. 2026.
Is AFT Pharmaceuticals' ROCE % too high?
AFT Pharmaceuticals' current ROCE % is 29.30%. The Drug Manufacturers industry median ROCE % is 7.04. AFT Pharmaceuticals' value of 29.30% is 316.2% above this industry median. Overall, AFT Pharmaceuticals has a GF Score™ of 95/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does AFT Pharmaceuticals' ROCE % compare to ZTS and UTHR?
AFT Pharmaceuticals' ROCE % of 29.30% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.04. AFT Pharmaceuticals' value of 29.30% is 316.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.04, based on 964 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AFT Pharmaceuticals's current ROCE % of 29.30% is 316.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AFT Pharmaceuticals's current ROCE % is 29.30%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AFT Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, AFT Pharmaceuticals (NZSE:AFT) is currently considered Fairly Valued. The stock's GF Value™ is NZ$4.18, compared to a current price of NZ$3.91 — trading 6.5% below its estimated fair value. The current ROCE % is 29.30% and 316.2% above the Drug Manufacturers industry median of 7.04. AFT Pharmaceuticals' overall GF Score™ is 95/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For AFT Pharmaceuticals (NZSE:AFT), the current ROCE % is 29.30% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AFT Pharmaceuticals (NZSE:AFT) Overvalued in 2026?

Based on GuruFocus' analysis, AFT Pharmaceuticals stock appears to be undervalued. The current stock price of NZ$3.91 is trading 6.5% below its estimated GF Value™ of NZ$4.18. GuruFocus considers AFT Pharmaceuticals to be Fairly Valued.

Key valuation signals for NZSE:AFT:

  • ROCE %: 29.30%
  • GF Value™: NZ$4.18 vs. price of NZ$3.91 (6.5% below fair value)
  • GF Score™: 95/100 with 4 warning signs
  • Industry Position: 316.2% above the Drug Manufacturers median

No single metric tells the full story. See the NZSE:AFT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AFT Pharmaceuticals Business Description

Other Exchanges AFP:Australia
Address 129 Hurstmere Road, Level 1, Takapuna, Auckland, NTL, NZL, 0622
AFT Pharmaceuticals Ltd is a pharmaceutical distributor and developer of pharmaceutical intellectual property. Some of the products of the organization are Maxigesic dose forms, Capsaicin creams, Crystaderm, Kiwisoothe, Micolette, and others. The group has four operating segments based on geographical location being Australia, New Zealand, Asia, and the Rest of the world. It generates the majority of the revenue from Australia, which includes the sales and distribution activity relating to the Australian market.
95GF Score

Get the complete analysis for NZSE:AFT

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NZ$3.91
Price
NZ$4.18
GF Value